APRE Stock Analysis: Buy, Sell, or Hold?
APRE - Aprea Therapeutics, Inc. Common stock
$0.84
-0.02 (-2.50%)
▼
5d:
+30.97%
30d:
+32.06%
90d:
-6.05%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When APRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: APRE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: APRE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: APRE is currently trading at $0.84, which is considered extended relative to its 30-day fair value range of $0.59 to $0.77.
Technical Outlook: Technically, APRE is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $1.16.
Market Sentiment: APRE scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.55 (+323.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APRE is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $1.16.
Market Sentiment: APRE scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.55 (+323.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.59 -
$0.77
Company Quality Score
25/100
(STRONG SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price extended above range (+8.9% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: Trading 323.3% below Wall St target ($3.55)
- WARNING: Composite score 25/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.59 -
$0.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$1.16
Current Trend
Strong Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.89
Wall Street Target
$3.55
(+323.3%)
Revenue Growth (YoY)
-98.4%
Share & Embed Analysis
Last updated: August 30, 2026 4:35 AM ET
Data refreshes hourly during market hours. Next update: 5:35 AM
Data refreshes hourly during market hours. Next update: 5:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 29 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 31 SELL |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 43 HOLD |
